9 studies on Matrixyl curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 6 published Matrixyl COA source records from third-party laboratories, covering 5 publicly attributable vendor identities. Across 6 records with positive numeric purity, the arithmetic mean is 99.58%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 0 records report measured amount more than 10% below the label. The latest recorded test date is 2026-07-18. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-07-18. Aggregate calculated: 2026-10-18T04:25:42.642317+00:00. Calculation time is not a laboratory observation date.
Within that total, 1 source record has unresolved vendor identity. It remains in corpus-level lab evidence and is excluded from named-vendor rankings.
Recent source records: #68561 (99.67%) · #68253 (99.41%) · #97576 (99.795%) · #39134 (99.67%) · #39892 (99.07%) · #86834 (99.874%)
This research provides crucial insights for the rational design of peptide-based cosmetic ingredients, particularly those targeting **collagen stimulation**. Understanding how subtle changes in peptide sequence (e.g.,…
This research introduces a multi-functional biomaterial with dual properties: a potent, self-assembling hydrogel and a selective anti-cancer agent. For researchers and developers in the peptide space, this demonstrate…
The study yielded compelling results, demonstrating that AAH exhibited significantly lower toxicity in HaCaT cells compared to the positive control, matrixyl, with cell viability remaining robust at 81.52% for AAH-tre…
**Matrixyl-containing formulations should not be assumed superior to simple emollients in clinical radiotherapy settings** simply because of their multi-ingredient, peptide-enhanced formulation. Clinicians and formula…
This research presents a highly promising dual-action therapeutic candidate, **3.1-PP4**, for treating complex skin injuries. By combining potent, broad-spectrum antimicrobial action against highly resistant bacteria …
Free, no account — handy when you're working with Matrixyl.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account